These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 15665152)

  • 1. Managing attention deficit/hyperactivity disorder: unmet needs and future directions.
    Steer CR
    Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i19-25. PubMed ID: 15665152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
    Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ;
    Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder.
    Hazell P
    Australas Psychiatry; 2010 Dec; 18(6):556-9. PubMed ID: 21117844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit hyperactivity disorder in adults.
    Bellak L; Black RB
    Clin Ther; 1992; 14(2):138-47. PubMed ID: 1351794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attention-deficit/hyperactivity disorder: management.
    Szymanski ML; Zolotor A
    Am Fam Physician; 2001 Oct; 64(8):1355-62. PubMed ID: 11681777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention-deficit/hyperactivity disorder in children and adolescents: closing diagnostic, communication, and treatment gaps.
    Vierhile A; Robb A; Ryan-Krause P
    J Pediatr Health Care; 2009; 23(1 Suppl):S5-23. PubMed ID: 19084757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment choices and experiences in attention deficit and hyperactivity disorder: relations to parents' beliefs and attributions.
    Johnston C; Seipp C; Hommersen P; Hoza B; Fine S
    Child Care Health Dev; 2005 Nov; 31(6):669-77. PubMed ID: 16207224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond the 'typical' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults.
    Vaughan BS; Wetzel MW; Kratochvil CJ
    Int Rev Psychiatry; 2008 Apr; 20(2):143-9. PubMed ID: 18386204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptability of behavioral and pharmacological treatments for attention-deficit/hyperactivity disorder: relations to child and parent characteristics.
    Johnston C; Hommersen P; Seipp C
    Behav Ther; 2008 Mar; 39(1):22-32. PubMed ID: 18328867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
    Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention-deficit/hyperactivity disorder: are we medicating for social disadvantage? (Against).
    Efron D
    J Paediatr Child Health; 2006 Sep; 42(9):548-51. PubMed ID: 16925543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attention deficit/hyperactivity disorder: a review and update.
    Cormier E
    J Pediatr Nurs; 2008 Oct; 23(5):345-57. PubMed ID: 18804015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of comorbidity in conduct disorder with attention-deficit hyperactivity disorder (ADHD).
    Turgay A
    Essent Psychopharmacol; 2005; 6(5):277-90. PubMed ID: 16222912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attention deficit hyperactivity disorder in preschool children.
    Greenhill LL; Posner K; Vaughan BS; Kratochvil CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):347-66, ix. PubMed ID: 18295150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention-deficit/hyperactivity disorder: a personal perspective.
    Ginsberg ML
    Adolesc Med State Art Rev; 2008 Aug; 19(2):339-51, xi-xii. PubMed ID: 18822837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.